OPTIMER PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Optimer Pharmaceuticals, Inc. Following Announcement Of Proposed Sale Of Company To Cubist Pharmaceuticals, Inc.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) announce that KSF has commenced an investigation into the Board of Directors of Optimer Pharmaceuticals, Inc. (“Optimer” or the “Company”) (NASDAQ GS: OPTR) in connection with their conduct related to the sale of the Company to Cubist Pharmaceuticals, Inc. (NASDAQ GS: CBST). Under the terms of the proposed transaction, shareholders of Optimer will receive $10.75 in cash for each share of Optimer common stock that they own. In addition, each Optimer shareholder will receive a contingent value right entitling the holder to receive an additional one-time cash payment of up to $5.00 for each share that they own if certain net sales of Optimer’s DIFICID drug are achieved.

KSF’s investigation is focusing on whether Optimer and/or its officers and directors secured sufficient value for the shareholders of the Company, violated their fiduciary duties, and/or violated state or federal securities laws.

If you have information that would assist KSF in its investigation, or would like to discuss your legal rights, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( lewis.kahn@ksfcounsel.com) or attorney Michael Palestina ( michael.palestina@ksfcounsel.com) toll free at 855-768-1857 or via cell phone any time at 504-236-7315.

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on transactional litigation, as well as securities class action and shareholder derivative litigation. With offices in New York and Louisiana, KSF's lawyers have significant experience litigating complex securities class actions nationwide on behalf of both institutional and individual shareholders.

To learn more about KSF, you may visit www.ksfcounsel.com.

Copyright Business Wire 2010

If you liked this article you might like

The Deal: Cubist Commits $1.6B to Bolster Antibiotics Portfolio

Comcast, Cubist Jump Pre-market Amid Cautious Trading

Morning Briefing: 10 Things You Should Know

Cubist Becomes Dominant Antibiotic Seller With Optimer, Trius Buys

5 Stocks Poised for Breakouts